JHPCY (Jiangsu Hengrui Pharmaceuticals Co) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JHPCY Jiangsu Hengrui Pharmaceuticals Co Ltd JHPCY
71 GF Score
Price $13.60
GF Value $15.12
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Jiangsu Hengrui Pharmaceuticals Co Defensive Interval Ratio?

JHPCY
71GF Score
Jiangsu Hengrui Pharmaceuticals Co Ltd JHPCY
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Jiangsu Hengrui Pharmaceuticals Co (JHPCY) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued. The current stock price of $13.60 is trading 10.1% below its estimated GF Value™ of $15.12. GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.

Key valuation signals for JHPCY:

  • Defensive Interval Ratio:
  • GF Value™: $15.12 vs. price of $13.60 (10.1% below fair value)
  • GF Score™: 71/100 with 1 warning sign

No single metric tells the full story. See the JHPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Hengrui Pharmaceuticals Co Business Description

Address No. 7, Kunlunshan Road, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222000
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
71GF Score

Get the complete analysis for JHPCY

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.60
Price
$15.12
GF Value